Watch experts discuss the latest data in immunotherapy as well as strategies for managing patients with advanced RCC.
This activity is intended for oncologists, urologists, nephrologists, nurses and nurse practitioners, pharmacists, and other healthcare providers who manage patients with renal cell carcinoma (RCC).
The goal of this activity is to increase understanding of the latest advances in the use of checkpoint inhibition in patients with advanced RCC.
Learning Objectives:
- Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors (ICIs) and other immunotherapies alone or in combination in the treatment of advanced RCC
- Have increased knowledge regarding the impact of recent clinical data on the treatment paradigm for patients with advanced RCC
- Demonstrate greater confidence in their ability to work with the interprofessional team to recognize and mitigate adverse events (AEs) in patients with advanced RCC
Approximate Time to Complete: 30 minutes
Credit Available: Jan. 30, 2020 - Jan. 30, 2021
Developed through a partnership between SITC and Medscape.
 |
|
Additional Lung Cancer Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)